Dilution Meets Regulation — Can Marvell Carry Both?
Marvell fell 16.48% Thursday as dilution concerns over its all-stock Lumentum deal compounded AI infrastructure policy risk. A long closing period, approvals, and integration costs already clouded the $1B-plus annual synergy target; slower data-center expansion could delay it further. Bulls see value in combining switches, DSPs, and lasers; bears warn Marvell’s falling share price erodes deal value. What will determine whether it has bottomed: approvals, customer retention, or synergies?